Tharimmune.

Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or 'uncontrollable itching' in PBC, a rare and orphan ...Tharimmune priced its $10 million public offering 10 million common shares at $1 per share. Shares of SenesTech, Inc. SNES were down 50% to $0.9181 after the company reported pricing of $5.0 ...Tharimmune says the main purpose of its reverse stock split is increasing the price of THAT shares. The company is doing this to get its shares above the $1 minimum bid price needed to remain on ...Nov 6, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ... Find the latest Tharimmune, Inc. (THAR) stock quote, history, news and other vital information to help you with your stock trading and investing.

Nov 17, 2023 · About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis. Expects completion and topline …Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The …

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company’s pre-clinical immuno ...

Hillstream BioPharma Inc is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism ...Nov 28, 2023 · Tharimmune Inc (NASDAQ: THAR) shares are trading lower by 71% to $1.00 Tuesday morning after the company priced an underwritten public offering of 10 million shares of common stock or pre-funded ... That public offering has Tharimmune selling 10 million shares of THAR stock. These shares are being sold for $1 each. Underwriters also have a 45-day option to acquire another 1.5 million shares ...Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), a rare orphan ...(NASDAQ: THAR) Tharimmune stock price per share is $0.75 today (as of Dec 1, 2023).

Tharimmune Inc (NASDAQ:THAR)’s traded shares stood at 69929.0 during the last session, with the company’s beta value hitting 2.78. At the close of trading, the stock’s price was $3.02, to imply a decrease of -15.88% or -$0.57 in intraday trading. The THAR share’s 52-week high remains $66.25, putting it -2093.71% down since that peak …

Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), …

Tharimmune, Inc., formerly Hillstream BioPharma, Inc., is a pre-clinical biotechnology company. The Company is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron med iated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an …14.45%. Get the latest Tharimmune Inc (THAR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …About Tharimmune, Inc. Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases.Tharimmune Inc (THAR) has seen a -23.43% fall in stock performance for the week, with a -10.37% decline in the past month and a -36.59% plunge in the past quarter. The volatility ratio for the week is 19.62%, and the volatility levels for the past 30 days are at 16.50% for THAR. The simple moving average for the past 20 days is -6.70% …Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in primary biliary cholangitis (PBC), …

Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in primary biliary cholangitis (PBC), a rare ...Tharimmune (NASDAQ: THAR) stock is taking off on Tuesday after the company underwent a name change. A filing with the Securities and Exchange Commission (SEC) reveals that Tharimmune has ...Nov 6, 2023 · Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or “uncontrollable itching” in PBC, a rare and orphan ... About Tharimmune, Inc. Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases.Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis November 6, 2023; Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. September 22, 2023

Tharimmune stock is falling on Tuesday after announcing a public offering. The company priced a 10 million share offering at $1 each. That’s well below its prior closing price and explains why ...My profile. Loading... Search securities... THARIMMUNE INC. THAR. Stock. NASDAQ ETH. End-of-day data. 1 D; 1 W; 1 M; 3 M; 1 Y. ProRealTime web is only available ...

Nov 27, 2023 · Tharimmune Inc THAR released phase 1 data with TH104, a proprietary transmucosal buccal film.. The first Phase 1 trial was a crossover study of TH104 transmucosal buccal film compared to a tablet ... Tharimmune Inc (NASDAQ: THAR) shares are trading lower by 9.7% to $0.19 during Monday's session, pulling back following Friday's strength, after the company announced it is undergoing a 1-for-25 ...26-Sept-2023 ... Find the latest Tharimmune Inc (THAR) discussion and analysis from iHub's community of investors.How much is Tharimmune stock worth today? ( NASDAQ: THAR) Tharimmune currently has 17,511,839 outstanding shares. With Tharimmune stock trading at $0.21 per share, the total value of Tharimmune stock (market capitalization) is $3.68M. Tharimmune stock was originally listed at a price of $3.48 in Jan 12, 2022.Tharimmune, Inc. (THAR Quick Quote THAR - Free Report) announced data from an early-stage study on TH104 and the development timeline for a phase IIa study in chronic pruritis in primary biliary ...Tharimmune, Inc., formerly Hillstream BioPharma, Inc., is a pre-clinical biotechnology company. The Company is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers.14.45%. Get the latest Tharimmune Inc (THAR) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and …06-Nov-2023 ... Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and ...Tharimmune shares opened at $2.93, later reaching a high of $4.79. The stock recently sold for $4.20, up 46%, at around 10:10 a.m. ET. Earlier Monday, Tharimmune said that a Phase 1 study for ...

Tharimmune, Inc., formerly Hillstream BioPharma, Inc., is a pre-clinical biotechnology company. The Company is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. The Companyâ s lead product candidate is HSB-1216, an …

The stock price for Tharimmune ( NASDAQ: THAR) is $ 3.04 last updated November 24, 2023, 11:14 AM PST. Q.

Company Info Tharimmune Inc. 1200 Route 22 East. Suite 2000. Bridgewater New Jersey 08807. United States. Website. Map. Employees 2. Sector Biotechnology. Nov 28, 2023 · Tharimmune, Inc. THAR announced data from an early-stage study on TH104 and the development timeline for a phase IIa study in chronic pruritis in primary biliary cholangitis (“PBC”) patients. About Tharimmune, Inc. Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases.Tharimmune priced its $10 million public offering 10 million common shares at $1 per share. Shares of SenesTech, Inc. SNES were down 50% to $0.9181 after the company reported pricing of $5.0 ...6 days ago ... Tharimmune (NASDAQ: THAR) is one of those little poster boy stocks to see how the funding of development pharma companies works.Tharimmune Inc. stock performance at a glance Check Tharimmune Inc.’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. THAR Stock PerformanceAbout Tharimmune, Inc. Tharimmune, Inc. is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases.6 days ago ... Tharimmune, Inc. (NASDAQ: THAR) announced the pricing of an underwritten public offering of 10,000,000 shares of common stock sold at $1.00 ...Tharimmune believes the completed phase 1 data coupled with the phase 1 pharmacokinetic bridging study in the United States may complement a phase 2a efficacy study to be launched next year in chronic pruritis in PBC as we begin engaging regulatory authorities in both the US and the EU. The phase 2a trial is planned as a multiple …

In addition, Tharimmune Inc saw -59.54% in overturn over a single year, with a tendency to cut further losses. Stock Fundamentals for THAR. The total capital return value is set at -455.13, while invested capital returns managed to touch -1,038.60. Equity return is now at value -147.31, with -124.01 for asset returns.Last Revised: June 9, 2023 These terms and conditions of use (the “Terms”) govern your use of our online interfaces and properties (e.g., websites and mobile ...Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ...Tharimmune, Inc., formerly Hillstream BioPharma, Inc., is a pre-clinical biotechnology company. The Company is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron med iated cell death (IMCD) for treatment-resistant cancers. The Company’s lead product candidate is HSB-1216, an …Instagram:https://instagram. microsoft closing pricegle 63s amg coupemsci inc stockjanus henderson enterprise fund Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ... how to invest in apple companyquarters with value 26-Sept-2023 ... Find the latest Tharimmune Inc (THAR) discussion and analysis from iHub's community of investors.Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive ... ninjatrader fees Nov 6, 2023 · Tharimmune, Inc., formerly Hillstream BioPharma, Inc., is a pre-clinical biotechnology company. The Company is engaged in developing therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for treatment-resistant cancers. Hillstream BioPharma Inc is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism ...